1 |
NAME OF REPORTING PERSON
Biotechnology Value Fund, L.P. | ||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) x
(b) o | |
3 |
SEC USE ONLY
| ||
4 |
SOURCE OF FUNDS
WC | ||
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
¨ | |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 | |
8 |
SHARED VOTING POWER
2,045,373 | ||
9 |
SOLE DISPOSITIVE POWER
0 | ||
10 |
SHARED DISPOSITIVE POWER
2,045,373 | ||
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,045,373 | ||
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o | |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.6% | ||
14 |
TYPE OF REPORTING PERSON
PN |
1 |
NAME OF REPORTING PERSON
Biotechnology Value Fund II, L.P. | ||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) x
(b) o | |
3 |
SEC USE ONLY
| ||
4 |
SOURCE OF FUNDS
WC | ||
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
¨ | |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 | |
8 |
SHARED VOTING POWER
1,421,900 | ||
9 |
SOLE DISPOSITIVE POWER
0 | ||
10 |
SHARED DISPOSITIVE POWER
1,421,900 | ||
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,421,900 | ||
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o | |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.2% | ||
14 |
TYPE OF REPORTING PERSON
PN |
1 |
NAME OF REPORTING PERSON
BVF Investments, L.L.C. | ||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) x
(b) o | |
3 |
SEC USE ONLY
| ||
4 |
SOURCE OF FUNDS
WC | ||
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
¨ | |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 | |
8 |
SHARED VOTING POWER
5,096,800 | ||
9 |
SOLE DISPOSITIVE POWER
0 | ||
10 |
SHARED DISPOSITIVE POWER
5,096,800 | ||
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,096,800 | ||
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o | |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.4% | ||
14 |
TYPE OF REPORTING PERSON
OO |
1 |
NAME OF REPORTING PERSON
Investment 10, L.L.C. | ||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) x
(b) o | |
3 |
SEC USE ONLY
| ||
4 |
SOURCE OF FUNDS
WC | ||
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
¨ | |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 | |
8 |
SHARED VOTING POWER
528,000 | ||
9 |
SOLE DISPOSITIVE POWER
0 | ||
10 |
SHARED DISPOSITIVE POWER
528,000 | ||
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
528,000 | ||
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o | |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.2% | ||
14 |
TYPE OF REPORTING PERSON
OO |
1 |
NAME OF REPORTING PERSON
BVF Partners L.P. | ||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) x
(b) o | |
3 |
SEC USE ONLY
| ||
4 |
SOURCE OF FUNDS
OO | ||
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
¨ | |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 | |
8 |
SHARED VOTING POWER
9,092,073 | ||
9 |
SOLE DISPOSITIVE POWER
0 | ||
10 |
SHARED DISPOSITIVE POWER
9,092,073 | ||
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,092,073 | ||
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o | |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20.4% | ||
14 |
TYPE OF REPORTING PERSON
PN, HC |
1 |
NAME OF REPORTING PERSON
BVF Inc. | ||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) x
(b) o | |
3 |
SEC USE ONLY
| ||
4 |
SOURCE OF FUNDS
OO | ||
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
¨ | |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 | |
8 |
SHARED VOTING POWER
9,092,073 | ||
9 |
SOLE DISPOSITIVE POWER
0 | ||
10 |
SHARED DISPOSITIVE POWER
9,092,073 | ||
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,092,073 | ||
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o | |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20.4% | ||
14 |
TYPE OF REPORTING PERSON
HC, CO |
1 |
NAME OF REPORTING PERSON
Mark N. Lampert | ||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) x
(b) o | |
3 |
SEC USE ONLY
| ||
4 |
SOURCE OF FUNDS
OO | ||
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
¨ | |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
USA | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 | |
8 |
SHARED VOTING POWER
9,092,073 | ||
9 |
SOLE DISPOSITIVE POWER
0 | ||
10 |
SHARED DISPOSITIVE POWER
9,092,073 | ||
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,092,073 | ||
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o | |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20.4% | ||
14 |
TYPE OF REPORTING PERSON
IN |
Date of
Transaction |
Type of
Securities |
Price Per Share |
BVF |
ILL10 |
BVF2 |
BVLLC |
Exchange |
Type of
Transaction |
09/17/2009 |
Common Stock |
5.2500 |
920,000 |
320,000 |
660,000 |
2,100,000 |
NASDAQ |
SALE |
Exhibit 99.1 |
Joint Filing Agreement by and among Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., Investment 10, L.L.C., BVF Partners L.P., BVF Inc. and Mark N. Lampert, dated September 21, 2009. |
BIOTECHNOLOGY VALUE FUND, L.P.* | ||||
By: |
BVF Partners L.P., its general partner | |||
By: |
BVF Inc., its general partner | |||
By: |
/s/ Mark N. Lampert | |||
Mark N. Lampert
President |
BIOTECHNOLOGY VALUE FUND II, L.P.* | ||||
By: |
BVF Partners L.P., its general partner | |||
By: |
BVF Inc., its general partner | |||
By: |
/s/ Mark N. Lampert | |||
Mark N. Lampert
President |
BVF INVESTMENTS, L.L.C.* | ||||
By: |
BVF Partners L.P., its manager | |||
By: |
BVF Inc., its general partner | |||
By: |
/s/ Mark N. Lampert | |||
Mark N. Lampert
President |
INVESTMENT 10, L.L.C.* | ||||
By: |
BVF Partners L.P., its investment manager | |||
By: |
BVF Inc., its general partner | |||
By: |
/s/ Mark N. Lampert | |||
Mark N. Lampert
President |
BVF PARTNERS L.P. * | |||
By: |
BVF Inc., its general partner | ||
By: |
/s/ Mark N. Lampert | ||
Mark N. Lampert
President |
BVF INC.* | ||
By: |
/s/ Mark N. Lampert | |
Mark N. Lampert
President |
/s/ Mark N. Lampert | |
Mark N. Lampert |